Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma

DISEASE CHARACTERISTICS:

Histologically confirmed recurrent or refractory B-cell lymphoma after at least 1 standard chemotherapy regimen

Low, intermediate, or high grade
CD22 antigen on at least 30% of tumor cells by flow cytometry
No lymphoblastic lymphoma, B-cell chronic lymphocytic leukemia, B-cell or pre-B-cell acute lymphocytic leukemia, or hairy cell leukemia

Measurable disease

Positive bone marrow not considered measurable
Circulating tumor cells in peripheral blood considered measurable
No CNS disease (leptomeningeal or parenchymal)
No lymphomatous or infectious pulmonary parenchymal disease
No baseline/pleural effusion
Ineligible for or refused autologous or allogeneic bone marrow transplantation NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age:

Over 18

Performance status:

ECOG 0-2

Life expectancy:

At least 3 months

Hematopoietic:

Platelet count greater than 50,000/mm^3
Absolute granulocyte count greater than 750/mm^3

Hepatic:

Bilirubin less than 1.5 mg/dL
SGPT less than 2 times upper limit of normal
Albumin greater than 75% lower limit of normal

Renal:

Creatinine no greater than 1.4 mg/dL OR
Creatinine clearance at least 60 mL/min

Cardiovascular:

Ejection fraction greater than 40% by MUGA or echocardiogram

Other:

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
HIV negative
No human anti-mouse antibody (HAMA) levels greater than 1 microgram/mL
No condition that may require stenting of ureters, stabilization of impending pathological fractures, or relief of airway, bowel, or biliary tract obstruction
No other concurrent illness that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

See Disease Characteristics

Chemotherapy:

See Disease Characteristics
At least 2 weeks since prior chemotherapy and recovered
No concurrent chemotherapy

Endocrine therapy:

No concurrent corticosteroids unless receiving stable maintenance dose prior to therapy

Radiotherapy:

No prior radiotherapy
No concurrent radiotherapy

Surgery:

Not specified

Other:

No other concurrent investigational agents